Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) FCF Margin (QoQ) (2012 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) FCF Margin (QoQ) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2,771.00
Mar 31, 2026 2,182.00
Dec 31, 2025 -1,107.00
Sep 30, 2025 -14,728.00
Jun 30, 2025 20,211.00
Mar 31, 2025 4,326.00
Dec 31, 2024 -1,816.00
Sep 30, 2024 -1,573.00
Jun 30, 2024 6,272.00
Mar 31, 2024 -3,629.00
Dec 31, 2023 -2,184.00
Sep 30, 2023 6,012.00
Jun 30, 2023 -9,060.00
Mar 31, 2023 7,365.00
Dec 31, 2022 -8,097.00
Sep 30, 2022 6,973.00
Jun 30, 2022 -1,194.00
Mar 31, 2022 -9,200.00
Dec 31, 2021 3,999.00
Sep 30, 2021 4,899.00